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Value of Sympathetic Innervation Imaging With
Iodine-123 MIBG in Heart Failure
Amil M. Shah, MD, MPH,* Mikhail Bourgoun, MD,* Jagat Narula, MD, PHD,†
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O B J E C T I V E S The aim of this study was to determine whether left ventricular ejection fraction
(LVEF) inﬂuences the relationship between abnormal myocardial sympathetic innervation imaging by
iodine 123 meta-iodobenzylguanidine (123I-mIBG) and outcomes in patients with heart failure (HF).
B A C KG ROUND In systolic HF, both abnormal 123I-mIBG imaging and reduced LVEF are associated
with higher risk of cardiovascular events. Whether 123I-mIBG imaging has the same predictive value
across the LVEF spectrum is unclear.
METHOD S Among 985 patients in the ADMIRE-HF (AdreView Myocardial Imaging for Risk Evalua-
tion in Heart Failure) trial with New York Heart Association functional class II or III HF and site-reported
LVEF 35%, the core laboratory–determined LVEFs were available for 901 subjects, ranging from 20%
to 58% (mean LVEF 34  7%), and was 35% in 386 subjects.
R E S U L T S The mean age of the study population was 62  12 years, 80% were male, and the
majority had New York Heart Association functional class II symptoms and HF of nonischemic etiology.
At all levels of LVEF, the 123I-mIBG heart-to-mediastinum ratio of 1.6 was associated with a higher risk
of death or potentially lethal arrhythmic event and of the composite of cardiovascular death, arrhythmic
event, and HF progression. Comparing subjects with LVEF 35% and 35%, there was no evidence of
effect modiﬁcation of LVEF on the risk associated with low heart-to-mediastinum ratio for death or
arrhythmic event (adjusted hazard ratio: 2.39 [95% conﬁdence interval (CI): 1.03 to 5.55] vs. 5.28 [95% CI:
1.21 to 23.02]; interaction p  0.48) and for the composite (adjusted hazard ratio: 1.80 [95% CI: 1.01 to
3.23] vs. 2.41 [95% CI: 1.11 to 5.23]; interaction; p  0.86). For death or arrhythmic event, the
heart-to-mediastinum ratio appeared to improve the risk discrimination beyond clinical and biomarker
data among both LVEF groups, with improvement in the model C-statistic (0.67 vs. 0.69, p  0.03) and
integrated discrimination improvement (p  0.0008).
CONC L U S I O N S 123I-mIBG imaging has prognostic value across a spectrum of LVEFs. Further
studies may be warranted to prospectively test the prognostic value of 123I-mIBG imaging in patients
with HF and an LVEF 35%. (J Am Coll Cardiol Img 2012;5:1139–46) © 2012 by the SIR
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1140atients with heart failure (HF) are at an
increased risk of death secondary to both
arrhythmia and HF progression regardless of
left ventricular ejection fraction (LVEF) (1,2).
When 45%, LVEF is a powerful predictor of
adverse events in patients with HF (3). However,
few measures are available to risk-stratify HF pa-
tients with a normal or mildly reduced LVEF. In
particular, although subjects with HF and an LVEF
35% are at an increased risk of sudden death
compared with persons without HF, there is cur-
rently no widely applicable method to risk-stratify
these patients and identify those who may benefit
from advanced therapies such as implantable
cardioverter-defibrillators (4).
Evaluations of LVEF are often imprecise, related
to interobserver variability, differences due to imag-
ing modality, and physiological variation over time
related to changes in loading conditions and heart
rate (5). The use of experienced core
laboratories appears to improve the uni-
formity of LVEF assessment by echocar-
diography in multicenter clinical trials,
and profession guidelines for their use are
now available (6). When LVEF cutoffs are
used in multicenter clinic trials, discor-
dance in LVEF results between the enroll-
ing site and a core laboratory is not un-
common (7).
Iodine 123 meta-iodobenzylguanidine
(123I-mIBG) is a radiopharmaceutical that
is selectively taken up into pre-synaptic
sympathetic nerve endings via the norepi-
nephrine reuptake system but is not me-
tabolized (8,9). Reductions in 123I-mIBG
ptake therefore may represent abnormalities of
re-synaptic norepinephrine reuptake or sustained
yperactivity of the sympathetic nervous system in
F with pre-synaptic norepinephrine depletion.
bnormal cardiac sympathetic innervation imaging
sing 123I-mIBG is associated with a higher risk of
ortality and morbidity among patients with HF
nd an LVEF 35% (10). Data regarding the
rognostic utility of 123I-mIBG in HF with an
VEF 35% are limited (11).
We hypothesized that the association of lower
eart-to-mediastinum ratio (H/M ratio) with mor-
ality and potentially lethal arrhythmic events will
e equivalent among HF patients across the spec-
rum of left ventricular (LV) systolic function. To
ain greater insight into the utility of 123I-mIBG
maging in HF with EF 35%, we performed a
ion
ionetrospective analysis of the ADMIRE-HF (Adre-iew Myocardial Imaging for Risk Evaluation in
eart Failure) trial database using LVEF deter-
ined by a core laboratory in which a subset of
atients had an LVEF 35%. Specifically, we
ought to assess for the presence of effect modifi-
ation of LVEF on the relationship between H/M
atio and the risk of death or potentially lethal
rrhythmic event and of cardiovascular death, ar-
hythmic event, or HF progression.
M E T H O D S
Patient population. The ADMIRE-HF trial was
he combination of 2 identical open-label, multi-
enter trials designed to provide prospective valida-
ion of the prognostic role of cardiac sympathetic
nnervation imaging using 123I-mIBG in patients
ith HF (12). The study enrolled 985 HF subjects
ho met the following inclusion criteria: New York
eart Association (NYHA) functional class II or
II symptoms, an ischemic or nonischemic cardio-
yopathy with a site-reported LVEF 35%, and
eceiving evidence-based medical therapy including
beta-blocker and angiotensin-converting enzyme
nhibitor or angiotensin receptor blocker. All en-
olled patients underwent planar imaging of the
nterior thorax at 15 min and 4 h after 123I-mIBG
injection. Subjects were followed for a median of 17
months to the primary composite endpoint of
cardiac death, potentially life-threatening arrhyth-
mic event, or HF progression. The extent of 123I-
IBG uptake was quantified at a core reading
acility, and clinical events were adjudicated by an
ndpoint adjudication committee as previously de-
cribed (13). A potentially life-threatening arrhyth-
ic event was defined as an episode of spontaneous
entricular tachycardia 30 s, resuscitated cardiac
rrest, or appropriate implantable cardioverter-
efibrillator discharge (antitachycardia pacing or
efibrillation). HF progression was defined as an
ncrease in NYHA functional class from II to III or
V or from III to IV. The primary results of the
DMIRE-HF trial were previously presented and
ublished (12).
Echocardiographic analysis. For trial inclusion, a
site-reported LVEF could be based on assessment
by echocardiography, radionuclide ventriculogra-
phy, electrocardiography-gated single-photon
emission computed tomography myocardial perfu-
sion imaging, contrast ventriculography, or cardiac
magnetic resonance. For quality assurance purposes,
sites also submitted echocardiograms to an inde-A B B R E V I A T I O N S
A N D A C R O N YM S
HF heart failure
H/M ratio heart-to-
mediastinum ratio
IDI integrated discriminat
improvement
LV left ventricular
LVEF left ventricular eject
fraction
123I-mIBG iodine 123
meta-iodobenzylguanidine
NYHA New York Heartpendent core laboratory for quantitative assessment
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1141of LV volumes and LVEFs. All echocardiograms
were evaluated in a core laboratory blinded to both
H/M ratio and clinical status. Ventricular volumes
were determined by the Simpson method in the
apical 4-chamber view, and LVEF was calculated
from volumes in the standard manner (14).
Of 901 patients with a core laboratory–
determined LVEF, 813 (90%) had site LVEF
measured by echocardiography. Of these 813 pa-
tients, the same echocardiogram was used for site
assessment and core laboratory analysis in 707
(87%). In the remaining 106 patients (13%), the
study used for site LVEF assessment and core
laboratory analysis were separated by a mean of 32
days (range, 1 to 439 days). In 88 patients (10%),
the site-reported LVEF was based on a modality
other than echocardiography, and in 59 (67%) of
these patients, the study used for site assessment of
LVEF was performed on a different day from the
echocardiogram analyzed by the core laboratory
(mean difference, 26 days; range, 1 to 50 days).
Statistical methods. We dichotomized subjects
ased on core laboratory–adjudicated LVEFs
35% or 35% to describe baseline clinical and
maging parameters. Continuous variables are pre-
ented as mean and SD unless otherwise specified,
nd between-group comparisons were performed
sing a Fisher exact test for categorical variables and
t test for continuous variables. Two-sided p values
0.05 were considered significant. Sample size was
llowed to float.
We assessed for effect modification using 2
ethods. First, multivariable Cox proportional haz-
rd models were used to evaluate for effect modifi-
ation of LVEF on the relationship between H/M
atio and the following outcomes: arrhythmic event
r death and a composite of cardiac death, HF
rogression, and arrhythmic event. All models ad-
usted for age, sex, baseline NYHA functional class,
F etiology (ischemic or nonischemic), diabetes
tatus, history of hypertension, and baseline B-type
atriuretic peptide level. A p value 0.05 was
onsidered significant.
Second, to better define the magnitude of risk
ssociated with low H/M ratio across the contin-
um of observed LVEFs, we used local regression
lots of the adjusted hazard ratio associated with an
/M ratio 1.6 by LVEF as a continuous measure
sing multivariable local regression (15). The haz-
rd ratio associated with a low H/M ratio was
lotted for every second percentile of LVEF incor-
orating patients with baseline LVEF within the 15
ercentiles above and below that point such that t0% of the study population contributed to each
ffect estimate.
To assess the incremental value of the H/M ratio
eyond clinical characteristics, biomarker data, and
VEF, analysis was restricted to 542 subjects (355
ith core laboratory LVEFs 35% and 187 with
VEFs 35%) with at least 475 days of follow-up.
ultivariable logistic regression models for the
ardiovascular composite outcome and for death or
rrhythmic event were built, either including or
xcluding H/M ratio data. All models adjusted for
ge, sex, baseline NYHA functional class, HF
tiology (ischemic or nonischemic), diabetes status,
istory of hypertension, baseline B-type natriuretic
eptide level, and core laboratory–adjudicated
VEF. The area under the receiver-operating char-
cteristic curve was expressed as the C-statistic and
ested whether pevent  pnonevent, where pevent is the
model predicted probability of an event from the
logistic regression model among individuals who
experienced an event and pnonevent is the model
predicted probability of an event among individuals
who did not experience an event. The model
C-statistic was compared among models with ver-
sus without H/M ratio. C-statistics were compared
using the Delong test (16). The integrated dis-
crimination improvement (IDI) was calculated
as IDI  (pwith H/M, event  pwithout H/M, event) 
pwith H/M, nonevent  pwithout H/M, nonevent), where
with H/M, event is the predicted probability of an
event from the logistic regression model containing
the H/M ratio data among individuals who experi-
enced an event, pwithout H/M, event is the predicted
probability of an event from the logistic regress-
ion model not containing the H/M ratio data
among individuals who experienced an event,
pwith H/M, nonevent is the predicted probability of an
event from the logistic regression model containing
H/M ratio data among individuals who did not
experience an event, and pwithout H/M, nonevent is the
predicted probability of an event from the logis-
tic regression model not containing H/M ratio
data among individuals who did not experience
an event (17).
R E S U L T S
Baseline characteristics. Of 985 subjects enrolled in
he ADMIRE-HF trial, 123I-mIBG imaging re-
ults, core laboratory– determined LVEFs, and
omplete follow-up were available for 901 subjects
91.5% of enrolled subjects) who were included in
his analysis. The mean site-reported LVEF was
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114227.1  6.2 (Fig. 1). One subject with a reported
VEF 35% at 2 days before 123I-mIBG imaging
was allowed to remain in the study based on an
earlier determination of 35%. The mean core labo-
ratory–adjudicated LVEF was 34.2  6.9 and 386
(43%) had an LVEF35%. Using a Bland-Altman
analysis of agreement between site-reported LVEF
and core laboratory–measured LVEF, the bias es-
timate for site-core laboratory LVEF was 7.1%
with 95% limits of agreement of 21.9% to 7.7%.
The mean LVEF of the 515 subjects with an
LVEF 35% was 29.5  3.7%, and the mean
LVEF of the 386 subjects with an LVEF 35%
was 40.4  5.0%. Subjects with an LVEF 35%
were more frequently female, more frequently had
HF of ischemic etiology, had lower body mass
index, and had lower baseline B-type natriuretic
peptide levels (Table 1). A modest, although statis-
tically significant, correlation was noted between
LVEF and H/M ratio as a continuous measure
(Pearson correlation coefficient  0.23, p 
0.0001).
LVEF, H/M ratio, and clinical events. Cumulative in-
cidence, event rates, and adjusted hazard ratio for
clinical events by LVEF category and H/M ratio
are shown in Table 2. Subjects with an LVEF
35% were at higher risk of both the composite of
Left Ventricular Ejection Fraction (%)
20 40
orted LVEF
b adjudicated LVEF
60
ution in the ADMIRE-HF Trial
-reported (pink columns) and echocardiography core laboratory–
ular ejection fraction (LVEF) (green columns). The mean site-re-
 6.2. The mean core laboratory–adjudicated LVEF was 34.2 
jects had an LVEF of 35%.cardiac death, arrhythmic event, and worsening HFand of death or arrhythmic event compared with
subjects with an LVEF35%. An H/M ratio1.6
as associated with an increased relative risk of
oth endpoints without evidence of significant ef-
ect modification by LVEF category (35% or
35%). Figure 2 illustrates the rate of death or
rrhythmic event by H/M ratio among 4 categories
f core laboratory LVEF, demonstrating consistent
rends toward higher event rates with an H/M ratio
1.6 in all categories. As demonstrated in Figure 3,
o significant heterogeneity of the relative risk
ssociated with an H/M ratio 1.6 was detected
cross the continuum of LVEF for either of the
linical endpoints.
Incremental value of H/M ratio beyond clinical charac-
teristics and LVEF in predicting clinical outcomes in
patients with HF and LVEF <35% and >35%. For the
ardiovascular composite endpoint, information on
/M ratio did not significantly affect the model
-statistic (Table 3). A small but significant im-
rovement in the IDI was noted, the magnitude of
hich was most prominent in the LVEF 35%
roup. For the outcome of death or arrhythmic
vent, the addition of H/M ratio led to signifi-
ant improvement in both the C-statistic and the
DI. For both measures, the magnitude of effect
Table 1. Baseline Characteristics by Core
Laboratory–Adjudicated LVEF
LVEF <35%
(n  515)
LVEF >35%
(n  386) p Value
LVEF, % 29.5 3.7 40.4 5.0
Age, yrs 61.6 12.0 62.8 11.7 0.13
Male 423 (82) 296 (77) 0.04
White race 381 (74) 292 (76) 0.59
NYHA functional class
III
89 (17) 62 (16) 0.65
Ischemic etiology 321 (62) 267 (69) 0.03
BMI, kg/m2 29.6 6.3 28.7 5.7 0.02
Diabetes 193 (37) 137 (35) 0.58
Hypertension 326 (63) 257 (67) 0.32
Dyslipidemia 381 (74) 275 (71) 0.37
Smoking 384 (75) 281 (73) 0.59
ACE inhibitor or ARB 483 (94) 358 (93) 0.59
Beta-blocker 475 (92) 350 (91) 0.47
Lipid-lowering
medication
376 (73) 291 (75) 0.44
eGFR, ml/min/1.73 m2 58.2 18.2 60.3 18.0 0.10
BNP, pg/ml* 170 (69–363) 107 (41–232) 0.0001
Values are mean  SD or n (%). *Median and interquartile range and
Kruskal-Wallis nonparametric test reported. Continuous variables are ex-
pressed as mean  SD.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker;
BMI body mass index; BMP B-type natriuretic peptide; eGFR estimated
glomerular ﬁltration rate; LVEF  left ventricular ejection fraction; NYHA Pe
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1143appeared greater among subjects with an LVEF
35%.
D I S C U S S I O N
Of 901 subjects enrolled in the ADMIRE-HF trial
with H/M ratio data and core laboratory LVEFs,
384 (43%) had an LVEF 35%. We found no
vidence of effect modification of LVEF on the
elationship between H/M ratio and risk, either of
eath or arrhythmic event or of the composite
ndpoint of cardiac death, arrhythmic event, and
orsening HF. For the outcome of death or ar-
hythmic event, information on H/M ratio ap-
eared to improve discrimination of predictive
odels beyond clinical, biomarker, and LVEF data,
articularly among subjects with an LVEF 35%.
Multiple single-center studies have demonstrated
an association between abnormal cardiac sympa-
thetic innervation imaging, reflected in a low H/M
ratio, and worse outcomes among patients with HF
(10). However, the majority of studies evaluated
patients with HF and low LVEF, and only limited
data exist regarding the performance of this test in
HF patients with normal or only slightly reduced
LVEF (18–20). In a multicenter study of 290
patients, Agostini et al. (18) demonstrated a rela-
tionship between H/M ratio and cardiovascular
events among the 191 subjects with an LVEF
35% but not among the 99 patients with an
LVEF 35%. Studies have demonstrated that the
washout rate, but not the H/M ratio, was predictive
of events among patients with an LVEF 35% to
40% (19,21). Among HF patients with a broad
range of core laboratory–adjudicated LVEFs, in-
cluding 386 subjects with an LVEF 35%, we did
not detect evidence of heterogeneity by LVEF in
the association between low H/M ratio and risk of
Table 2. Cumulative Incidence of Cardiovascular Events Amon
Versus >35% by H/M Ratio Category
LVEF <35% (n  51
Overall
H/M
Ratio <1.6
H/M
Ratio >1.6
Death 52 (10) 50 (12) 2 (2)
CV death 33 (6) 32 (7) 1 (1)
Arrhythmic event 48 (9) 44 (10) 4 (5)
Worsening HF 117 (23) 106 (24) 11 (13)
Arrhythmic event or death 95 (18) 89 (21) 6 (7)
CV composite 156 (30) 143 (33) 13 (16)
Values are n (%) or n (range). *Adjusted for age, sex, heart failure etiology, NY
CV  cardiovascular; HF  heart failure; H/M ratio  heart-to-mediastinum racardiovascular events.Although the risk of sudden death is especially
pronounced among HF patients with significant
LV dysfunction, it is also the most common cause
of cardiovascular death among patients with HF
and normal or slightly reduced systolic function,
accounting for 26% to 28% of total mortality (1,2).
However, the ability to effectively risk-stratify these
patients is limited. Although LVEF is a powerful
predictor of mortality and sudden death when
significantly reduced, it is less useful in risk-
stratifying those patients with normal or only
slightly reduced LVEF (45%) (3). Given the role
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Figure 2. Event Rates by LVEF and H/M Ratio
Rates of death or arrhythmic event by 4 categories of core laborato
ventricular ejection fraction (LVEF) and heart-to-mediastinum ratio (
above each column represent the event rate per 100 person-years,
and percentage of patients experiencing an event. Hazard ratios (H
using multivariable Cox proportional hazards models adjusting for
Heart Association (NYHA) functional class and log of baseline B-typ
atients With Core Laboratory–Adjudicated LVEF <35%
LVEF >35% (n  386)
HR (Range)* Overall
H/M
Ratio <1.6
H/M
Ratio >1.6 HR (Ran
21 (5) 20 (7) 1 (1)
13 (3) 12 (4) 1 (1)
14 (4) 13 (5) 1 (1)
48 (12) 40 (14) 8 (7)
2.39 (1.03–5.55) 33 (9) 31 (11) 2 (2) 5.28 (1.21–
1.80 (1.01–3.23) 64 (17) 55 (20) 9 (8) 2.41 (1.11–
nctional class, diabetes status, hypertension, and B-type natriuretic peptide leve
HR  hazard ratio; LVEF  left ventricular ejection fraction; other abbreviation aH/M Ratio
≥1.6
<1.6
(9%)
ry–adjudicated left
H/M ratio). Values
number of events,
Rs) were determined
baseline New York
e natriuretic peptideg P
5)
p Value
for
Interactionge)*
23.02) 0.48
5.23) 0.86
HA fu l.(BNP) level.
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1144of cardiac autonomic innervation in the pathogen-
esis of ventricular arrhythmias (22), sympathetic
innervation imaging has the potential to identify
subjects at increased risk of life-threatening ar-
rhythmia, although data regarding the relationship
between H/M ratio and spontaneous arrhythmias in
patients with implantable cardioverter-defibrillators (23)
or inducible arrhythmias on electrophysiological testing
Core Lab Adjudicated LVEF (%)
7 29 31 33 35 37 39 41
Core Lab Adjudicated LVEF (%)
7 29 31 33 35 37 39 41
Ratio <1.6 Across the LVEF Continuum
f the adjusted HR associated with an H/M ratio 1.6 by LVEF as a
ing multivariable Cox proportional hazards models. Refer to the
tails of plot derivation. All HR point estimates are adjusted for age,
y, NYHA functional class, diabetes status, hypertension, and BNP
vascular composite of cardiovascular death, arrhythmic event, or
; (B) death or arrhythmic event. CI  conﬁdence interval; other
re 2.(24) has been inconsistent. Our findings suggest that aow H/M ratio is associated with a higher risk of
eath or arrhythmic event across the spectrum of
VEFs, including HF patients with an LVEF
35%. Also, although limited by power, our ex-
loratory analysis of the impact of H/M ratio data
n model performance (C-statistic) and reclassifi-
ation indexes (IDI) suggests that for the outcome
f death or arrhythmic event, information on the
/M ratio improves risk discrimination beyond
linical, biomarker, and LVEF data. These findings
uggest that 123I-mIBG imaging may hold promise
o improve risk stratification among HF patients
ith an LVEF 35% if future adequately powered
rospective studies can confirm these hypothesis-
enerating findings.
Study limitations. All patients had a site-reported
VEF of 35%. Although we noted a quantitative
ore laboratory LVEF 35% in 386 patients (43%
f the trial population), the core laboratory LVEF
as still 40% in the majority of these (n  229,
59%) and was 45% in a large majority (n  324,
84%). These differences may partly relate to a
difference in timing and/or modality of study used
by site and core laboratory in nearly one-fourth of
subjects because the confidence limits for serial
assessments of the LVEF in an individual at 2 time
points are approximately 10% (25). Differences in
the remainder of cases may partly relate to inter-
reader variability, which approximates 7%, even
when both assessments are measured quantitatively
(5,25). Finally, in multicenter clinical trials using
LVEF cutoffs for inclusion, discordance between
enrolling site and core laboratory assessment is not
unusual (7). Although this analysis provides infor-
mation on the performance of sympathetic inner-
vation imaging in HF patients with lesser degrees of
impairment in LV systolic function, it does not
represent the HF with preserved ejection fraction
population. The timing between performance of the
echocardiogram read by the core laboratory and the
123I-mIBG imaging varied. The relationship be-
tween appropriate implantable cardioverter-
defibrillator therapy and sudden death is unclear.
HF progression determined by increased NYHA
functional class is subjective, although this endpoint
was centrally adjudicated. The analyses were under-
powered to detect an interaction by LVEF on the
relationship between the H/M ratio and clinical
events. They were similarly underpowered to detect
incremental benefit of the H/M ratio beyond
LVEF, biomarkers, and clinical data, especially
when stratified by LVEF. For the LVEF 35%A
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1145rhythmic event may be overfitted, although results
were qualitatively similar as observed in unadjusted
analyses. However, this population is the largest to our
knowledge with data on the H/M ratio and clinical
outcomes in HF patients with an LVEF 35%.
C O N C L U S I O N S
Myocardial sympathetic innervation imaging with
123I-mIBG has prognostic value across a broad
spectrum of LVEFs for death or arrhythmic event
and for cardiovascular death, arrhythmic event, and
Table 3. Indexes of the Incremental Value of H/M Ratio Beyond
Occurrence of Cardiovascular Events Among Patients With LVEF
Overall p Value
Cardiovascular composite
C-statistic
Without H/M ratio 0.72 0.14
With H/M ratio 0.73
IDI 1.09% 0.007
Arrhythmic event or death
C-statistic
Without H/M ratio 0.67 0.03
With H/M ratio 0.69
IDI 1.29% 0.0008
IDI  Integrated discrimination improvement; other abbreviations as in TableCommittee to Revise the ACC/ J Heart Fail 2010;1arrhythmic event in particular, 123I-mIBG imaging
appears to improve risk discrimination beyond clin-
ical and biomarker data regardless of the LVEF.
These findings suggest that further prospective
studies may be warranted to evaluate the prognostic
value of 123I-mIBG imaging in patients with HF
nd an LVEF 35%.
Reprint requests and correspondence: Dr. Amil M. Shah,
ardiovascular Division, Brigham and Women’s Hospi-
al, 75 Francis Street, Boston, Massachusetts 02115.
nical, Echocardiographic, and Biomarker Data in Predicting
5% and Those With LVEF >35%
EF <35% p Value LVEF >35% p Value
0.75 0.20 0.71 0.55
0.76 0.72
0.89% 0.04 2.25% 0.03
0.70 0.07 0.67 0.08
0.71 0.74
1.16% 0.02 3.36% 0.008HF progression. For the outcome of death or E-mail: ashah11@rics.bwh.harvard.edu.1
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